Related Experiment Video
Updated: Nov 9, 2025

Development of Leishmania Species Strains with Constitutive Expression of eGFP
Published on: April 21, 2023
Leishmaniasis: where are we and where are we heading?
Santanu Sasidharan1, Prakash Saudagar2
1Department of Biotechnology, National Institute of Technology, Warangal, Telangana, 506004, India.
Abstract:
Leishmaniasis is a zoonotic disease in humans caused by the bite of a parasite-infected sandfly. The disease, widely referred to as "poor man's disease," affects millions of people worldwide. The clinical manifestation of the disease depends upon the species of the parasite and ranges from physical disfigurement to death if left untreated. Here, we review the past, present, and future of leishmaniasis in detail. The life cycle of Leishmania sp., along with its epidemiology, is discussed, and in addition, the line of therapeutics available for treatment currently is examined. The current status of the disease is critically evaluated, keeping emerging threats like human immunodeficiency virus (HIV) coinfection and post kala-azar dermal leishmaniasis (PKDL) into consideration. In summary, the review proposes a dire need for new therapeutics and reassessment of the measures and policies concerning emerging threats. New strategies are essential to achieve the goal of leishmaniasis eradication in the next few decades.

